owlstone medical latest news, press mentions and upcoming ...the below is an example of the email...

1
Owlstone Medical latest news, press mentions and upcoming events Owlstone Medical have joined forces with Thermo Fisher Scientific, to advance the application of non-invasive breath sampling, addressing the challenges of early detection and precision medicine via the discovery and validation of novel biomarkers. Under the agreement, both groups will work to integrate the highly sensitive Thermo Scientific Q Exactive GC Hybrid Quadrupole-Orbitrap Mass Spectrometer into Owlstone Medical’s Breath Biopsy ® platform, which upon completion will then become a standard part of Owlstone Medical’s unique breath biomarker discovery process. Further to the sharing of scientific and technical expertise, this collaboration will be supported by a joint marketing and customer support efforts to expand the global reach of the Breath Biopsy platform. The 2019 Breath Biopsy Conference took place in Cambridge on 13 th and 14 th November. The Owlstone Medical team welcomed over 140 delegates for two-days of presentations, posters, discussions and networking. Day one saw keynote speakers Jane Hill and Jessica Lasky-Su present on infectious disease diagnosis and metabolomics respectively. Day two of the conference included a further keynote by George Hanna from Imperial College London and closed with a lively expert panel discussion on 'The next five years in breath research.' Alongside the main programme, delegates enjoyed the popular poster session and had the opportunity to get their hands on the new range of Breath Biopsy products, and meet our expert teams, who were on hand to answer questions about the platform. Owlstone Medical CEO Billy Boyle said, "I think this year's conference has been a great success. This is our second conference and it has doubled in size, bringing together people from very diverse fields, including analytical chemists to clinicians". “The conference enables us to foster a community where collaboration is a key aim. For me the key highlight of the conference was the range of the different speakers and the depth of experience among the delegates. I would like to say a massive thank you to everyone who attended this year's event and we look forward to welcoming you to next year's conference." Owlstone Medical has joined 3TR, a large-scale public-private research initiative that aims to provide new insights into the mechanisms of response and non-response to treatment within and across seven different immune-mediated diseases. The project unites renowned, interdisciplinary experts from 69 academic and industrial partner institutions, including multiple top-ten pharma, covering 15 European countries. The initiative will provide access to an unprecedented quantity of clinical data and samples of more than 50,000 patients across 50 ongoing and new clinical trials, ultimately aiming to discover and verify stratification biomarkers to improve patient management. Billy Boyle, co-founder and CEO at Owlstone Medical, said: “3TR’s ground-breaking approach to addressing this problem through integrated cross-disease analysis, led by leading academic, pharmaceutical, and other organizations, is one that Owlstone Medical is excited to be making a unique contribution to.” IN THE MEDIA Financial Times Owlstone Medical feature in article, 'Cambridge science parks attract record funding for 'spinouts'' READ THIS OWLSTONE BLOG Five Key Challenges in Breath Research Looking at the methodological, biological and analytical challenges of breath research READ THIS AWARD Life Science Company of the Year - Winner Cambridge Independent Science and Technology Award READ THIS events worldwide. J.P. Morgan Healthcare Conference 13-16 Jan 2020, San Francisco, USA Biomarkers Series UK 18-20 Feb 2020, Manchester, UK International Liver Conference 15-19 Apr 2020, London, UK - Booth 433 Visit our website: www.owlstonemedical.com Get in touch | Sign up for our Newsletter | | | The below is an example of the email newsletters sent out by Owlstone Medical. Click the button to get future newsletters sent direct to your inbox. SIGN UP TO THE NEWSLETTER

Upload: others

Post on 24-Aug-2020

5 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Owlstone Medical latest news, press mentions and upcoming ...The below is an example of the email newsletters sent out by Owlstone Medical. Click the button to get future newsletters

Billy Boyle, Owlstone Medical <[email protected]>21 January 2020 11:44Jonathan LawsonTEST | Owlstone Medical Enters Partnership with Thermo Fisher Scientific

Owlstone Medical latest news, pressmentions and upcoming events

Owlstone Medical have joined forces with Thermo Fisher Scientific, to advance the

application of non-invasive breath sampling, addressing the challenges of early detection

and precision medicine via the discovery and validation of novel biomarkers. Under the

agreement, both groups will work to integrate the highly sensitive Thermo Scientific™ Q

Exactive™ GC Hybrid Quadrupole-Orbitrap™ Mass Spectrometer into Owlstone Medical’s

Breath Biopsy® platform, which upon completion will then become a standard part of

Owlstone Medical’s unique breath biomarker discovery process.

Further to the sharing of scientific and technical expertise, this collaboration will be

supported by a joint marketing and customer support efforts to expand the global reach of

the Breath Biopsy platform.

The 2019 Breath Biopsy Conference took place in Cambridge on 13th and 14th November.

The Owlstone Medical team welcomed over 140 delegates for two-days of presentations,

posters, discussions and networking.

Day one saw keynote speakers Jane Hill and Jessica Lasky-Su present on infectious

disease diagnosis and metabolomics respectively. Day two of the conference included a

further keynote by George Hanna from Imperial College London and closed with a lively

expert panel discussion on 'The next five years in breath research.' Alongside the main

programme, delegates enjoyed the popular poster session and had the opportunity to get

their hands on the new range of Breath Biopsy products, and meet our expert teams, who

were on hand to answer questions about the platform.

Owlstone Medical CEO Billy Boyle said, "I think this year's conference has been a great

success. This is our second conference and it has doubled in size, bringing together people

from very diverse fields, including analytical chemists to clinicians".

“The conference enables us to foster a community where collaboration is a key aim. For me

the key highlight of the conference was the range of the different speakers and the depth of

experience among the delegates. I would like to say a massive thank you to everyone who

attended this year's event and we look forward to welcoming you to next year's conference."

Owlstone Medical has joined 3TR, a large-scale public-private research initiative that aims to

provide new insights into the mechanisms of response and non-response to treatment within

and across seven different immune-mediated diseases.

The project unites renowned, interdisciplinary experts from 69 academic and industrial

partner institutions, including multiple top-ten pharma, covering 15 European countries. The

initiative will provide access to an unprecedented quantity of clinical data and samples of

more than 50,000 patients across 50 ongoing and new clinical trials, ultimately aiming to

discover and verify stratification biomarkers to improve patient management.

Billy Boyle, co-founder and CEO at Owlstone Medical, said: “3TR’s ground-breaking

approach to addressing this problem through integrated cross-disease analysis, led by

leading academic, pharmaceutical, and other organizations, is one that Owlstone Medical is

excited to be making a unique contribution to.”

IN THE MEDIA

Financial Times

Owlstone Medical feature

in article, 'Cambridge

science parks attract

record funding for

'spinouts''

R E A D T H I S

OWLSTONE BLOG

Five Key Challenges in Breath Research

Looking at the

methodological, biological

and analytical challenges

of breath research

R E A D T H I S

AWARD

Life Science Company of the Year - Winner

Cambridge Independent

Science and Technology

Award

R E A D T H I S

events worldwide.

J.P. Morgan Healthcare Conference

13-16 Jan 2020, San Francisco, USA

Biomarkers Series UK

18-20 Feb 2020, Manchester, UK

International Liver Conference

15-19 Apr 2020, London, UK - Booth 433

Visit our website: www.owlstonemedical.com

Get in touch | Sign up for our Newsletter | | |

The below is an example of the email newsletters sent out by Owlstone Medical. Click the button to get future newsletters sent direct to your inbox.

SIGN UP TO THE NEWSLETTER